Bottom line
RYCFX vs FBTAX: the short answer
RYCFX (Biotechnology Fund) and FBTAX (Fidelity Advisor Biotechnology Fund) are both mutual funds.
FBTAX is cheaper at 0.94% vs 2.38% — a difference of $144 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs +3.0% for RYCFX (reporting dates differ).
Updated Nov 19, 2026
RYCFX vs FBTAX side by side
| RYCFX | FBTAX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Guggenheim | Fidelity |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.94% |
| Annual cost per $10k | $238 | $94 |
| 10-yr cost on $10k (prospectus) | $2,763 | $1,663 |
| Max front load | 0% | — |
| 12b-1 fee | 1% | 0.25% |
| 1-yr return | +28.4% | +31.5% |
| 5-yr return (annualized) | +3.0% | +6.4% |
| 10-yr return (annualized) | +4.8% | +7.7% |
| Best quarter | +28.0% | +30.3% |
| Worst quarter | −22.7% | −27.8% |
| Net assets (fund) | $136.8M | $2.2B |
| Number of holdings | 74 | 129 |
| Portfolio turnover | 75% | 54% |
| Returns as of | Dec 31, 2025 | Sep 30, 2026 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | FBTAX | Difference |
|---|---|---|---|
| 2025 | +29.4% | +39.6% | −10.1% |
| 2024 | −1.7% | +5.3% | −7.1% |
| 2023 | +5.0% | +10.7% | −5.7% |
| 2022 | −13.9% | −8.0% | −6.0% |
| 2021 | +0.8% | −3.6% | +4.4% |
| 2020 | +20.9% | +32.2% | −11.3% |
| 2019 | +23.8% | +25.7% | −1.9% |
| 2018 | −9.9% | −3.8% | −6.1% |
| 2017 | +28.4% | +25.8% | +2.6% |
| 2016 | −20.3% | −23.6% | +3.3% |
Source: Fund prospectus bar charts
Holdings overlap
11 of RYCFX's top 25 holdings also appear in FBTAX's top 25.
| Holding | RYCFX | FBTAX |
|---|---|---|
| Abbvie Inc | 8.17% | 14.71% |
| Amgen Inc | 5.05% | 2.37% |
| Gilead Sciences Inc | 4.49% | 5.70% |
| Vertex Pharmaceuticals Inc | 4.32% | 1.39% |
| Revolution Medicines Inc | 2.48% | 3.00% |
| Alnylam Pharmaceuticals Inc | 2.36% | 3.62% |
| Moderna Inc | 2.15% | 1.60% |
| Biogen Inc | 2.13% | 2.71% |
| Natera Inc | 2.12% | 1.43% |
| Insmed Inc | 1.79% | 3.05% |
| Argenx Se | 1.48% | 3.00% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
FAQ
What is the difference between RYCFX and FBTAX?
Which is cheaper, RYCFX or FBTAX?
Should I own both RYCFX and FBTAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.